Another study touting the safety of toremifene over tamoxifen.

V

Vegas

New member
Chem Res Toxicol. 2006 Mar;19(3):421-5.

Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.

Umemoto A, Lin CX, Ueyama Y, Komaki K, Santosh Laxmi YR, Shibutani S.

Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan. aummt@clin.med.tokushima-u.ac.jp

Tamoxifen (TAM) causes cancer in rat liver and human endometrium, whereas the carcinogenicity of its chlorinated analogue toremifene (TOR) has not been observed. To elucidate the genotoxicity of TOR, the capability of forming DNA adducts by TOR was examined in the leukocytes of patients treated with TOR. Leukocytes were collected from 27 breast cancer patients (57.7 +/- 11.4 years old) taking TOR (40 mg/day for 25 patients, 80 mg/day for one patient, and 120 mg/day for one patient; average duration, approximately 12 months) and 20 untreated breast cancer patients (58.2 +/- 12.3 years old). The DNA extracted was analyzed by (32)P-postlabeling/high-performance liquid chromatography. No DNA adducts were detected in the leukocytes of either TOR-treated or nontreated patients. Our results contrast to the previous observation detecting TAM-DNA adducts in several patients treated with TAM, indicating that TOR is less genotoxic to humans.
PMID: 16544947 [PubMed - in process]
 
There are some indicates that long, prolonged use of tamoxifen (i.e. nolva) can lead to cancer in a small minority of users. Toremifene, another SERM like nolva and clomid that pretty much offers the same benefits, does not appear to present the same risks (i.e. it won't cause cancer in anybody at all).
 
Aboot said:
Chem Res Toxicol. 2006 Mar;19(3):421-5.

Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.

Umemoto A, Lin CX, Ueyama Y, Komaki K, Santosh Laxmi YR, Shibutani S.

Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan. aummt@clin.med.tokushima-u.ac.jp

Tamoxifen (TAM) causes cancer in rat liver and human endometrium, whereas the carcinogenicity of its chlorinated analogue toremifene (TOR) has not been observed. To elucidate the genotoxicity of TOR, the capability of forming DNA adducts by TOR was examined in the leukocytes of patients treated with TOR. Leukocytes were collected from 27 breast cancer patients (57.7 +/- 11.4 years old) taking TOR (40 mg/day for 25 patients, 80 mg/day for one patient, and 120 mg/day for one patient; average duration, approximately 12 months) and 20 untreated breast cancer patients (58.2 +/- 12.3 years old). The DNA extracted was analyzed by (32)P-postlabeling/high-performance liquid chromatography. No DNA adducts were detected in the leukocytes of either TOR-treated or nontreated patients. Our results contrast to the previous observation detecting TAM-DNA adducts in several patients treated with TAM, indicating that TOR is less genotoxic to humans.
PMID: 16544947 [PubMed - in process]
Click to expand...
Good read! I had been thinking about switching. Yes it's being made under the name Fareston
 
Last edited:
Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly antiestrogenic in rats and humans and estrogenic in mice. In rats, toremifene causes regression of established dimethylbenzanthracene (DMBA)-induced mammary tumors. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, ie, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor.

Toremifene causes a decrease in the estradiol-induced vaginal cornification index in some postmenopausal women, indicative of its antiestrogenic activity. Toremifene also has estrogenic activity as shown by decreases in serum gonadotropin concentrations (FSH and LH). It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

The plasma concentration time profile of toremifene declines biexponentially after absorption with a mean distribution half-life of about 4 hours and an elimination half-life of about 5 days. Elimination half-lives of major metabolites, N-demethyltoremifene and (deaminohydroxy) toremifene were 6 and 4 days, respectively. Mean total clearance of toremifene was approximately 5L/h.

Toremifene is well absorbed after oral administration and absorption is not influenced by food. Peak plasma concentrations are obtained within 3 hours. Toremifene displays linear pharmacokinetics after single oral doses of 10 to 680 mg. After multiple dosing, dose proportionality was observed for doses of 10 to 400 mg. Steady-state concentrations were reached in about 4-6 weeks. Toremifene has an apparent volume of distribution of 580 L and binds extensively(>99.5%) to serum proteins, mainly to albumin
 
Micromegas said:
What happens in rodents doesn't necessarly happen in Humans. I want to see a study showing a link in HUMANS.
Click to expand...


Must we have this discussion about every single study? I assume that everyone takes that for granted. Take the study for what it is worth and leave it at that.

Now I'm going to go read the mountain of research conducted using healthy, athletic, male bodybuilders in the 20s and 30s who use anabolic steroids...
 
This product big on the imminst boards, you know the infinite life spaners. You will find little help there though for your needs. Unless all you been eating only carrots and are biggness come to town!
 
humanos :)

Cancer Chemother Pharmacol. 2000;45(5):402-8. Related Articles, Links


Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.

Ellmen J, Werner D, Hakulinen P, Keiling R, Fargeot P, Falkson G, Bezwoda WR.

Orion Corporation, Orion Pharma, Clinical R & D, Turku, Finland. juha.ellmen@orion.fi

PURPOSE: The purpose of the study was to compare hormonal effects of three toremifene doses, 20 mg (TOR20), 40 mg (TOR40) and 60 mg (TOR60) administered daily, in postmenopausal women with advanced breast cancer. METHODS: The study was randomized and open label in three parallel groups. Biochemical variables were identified as the serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and sex hormone binding globulin (SHBG). The changes were compared with objective clinical responses and to progression-free time. Adverse reactions and liver function test (aspartate aminotransferase, ASAT) were assessed for safety. RESULTS: A total of 260 patients were randomly grouped (90 to TOR20, 81 to TOR40 and 89 to TOR60). Of these patients 29, 29 and 22 completed at least 3 months of treatment and the results were analyzed for biochemical variables. All treatments had intrinsic estrogen agonist activity by decreasing of serum FSH and LH and by increasing of SHBG during the first 3 months (P < 0.01). Dose TOR20 showed slightly longer times to exert maximum estrogenic effects than did the two higher doses. No increases in liver function tests were seen in any of the groups. Objective response rates were 24.4, 39.5 and 32.6% (P = 0.01) and median times-to-progression were 206, 189 and 196 days in TOR20, TOR40 and TOR60, respectively (P = 0.913). Fewer responses were observed in the TOR20 group than in TOR40 (P = 0.05). Adverse events were reported in 19, 23 and 30 patients in the treatment groups (P = 0.20). The most frequently reported events were hot flushes and nausea. These were mostly mild or moderate, and only 1.5% of treatments was discontinued due to toxicity. CONCLUSIONS: Toremifene doses of 40 and 60 mg daily were effective and safe treatments of breast cancer in postmenopausal women, and no differences in their biochemical or clinical effects were seen. Toremifene at 20 mg/day had similar but slightly less potent antiestrogenic and estrogenic effects than the two higher doses.
 
Aboot said:
Must we have this discussion about every single study? I assume that everyone takes that for granted. Take the study for what it is worth and leave it at that.

Now I'm going to go read the mountain of research conducted using healthy, athletic, male bodybuilders in the 20s and 30s who use anabolic steroids...
Click to expand...


I've seen studies done on rats where when injected with the amount of testosterone(By bodyweight) that humans are injected with...Within a few weeks they had cancerous growth all in their organs. Obviously this doesn't happen with humans. (Used as evidence 'steroids are deadly' by politicans alot)

Different species react differently to different chemicals.
 
Aboot said:
Now I'm going to go read the mountain of research conducted using healthy, athletic, male bodybuilders in the 20s and 30s who use anabolic steroids...
Click to expand...
:hahano:
 
DocJ said:
:hahano:
Click to expand...



What's so funny?


He makes it seem like the only humans using Tamoxifen or toremifene are bodybuilders. This is nonsense.


Both of these drugs are used to treat breast cancer in women. Meaning both drugs have tons of scientific studies concerning them when taken by humans. Posting a study dealing with rats is basically irrelevant when it's taken by thousands of humans everyday.


All I asked for was a study showing this same link in humans who take the drug. Considering so many humans do indeed take it.


Fact of the matter is...Studies show it is NOT known to cause liver cancer in humans even though it does in rats. Proof studies done on rats have no relevancy to humans.

Does tamoxifen cause other types of cancer?
Click to expand...

Although tamoxifen can cause liver cancer in particular strains of rats, it is not known to cause liver cancer in humans. It is clear, however, that tamoxifen can sometimes cause other liver toxicities in patients, which can be severe or life threatening. Doctors may order blood tests from time to time to check liver function.
Click to expand...

http://www.cancer.gov/cancertopics/factsheet/Therapy/tamoxifen

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9747868&dopt=Books
 
Last edited:
HeywoodJAblome said:
I thought we weren't supposed to post links of companies that aren't sponsors here...

I know of a company that has it, just don't wanna break the rules.
Click to expand...


As long it isn't an illegal source your good to go. Everyone posts about ology becausre they have alot of what we need and they support the board. If they don't have it your not hurting them.
 
You must log in or register to reply here.

Similar threads

V
How to Read Your Liver Blood Test Results (Please read)
Replies
14
Views
1K
Milton
Milton
V
How to Read Your Liver Blood Test Results (Please read)
Replies
6
Views
1K
.Vision.
V
SicVic
The Basic Guide post cycle therapy (pct) / Ancilleries etc..
Replies
0
Views
2K
SicVic
SicVic
J
Steroids over 40
2 3
Replies
51
Views
63K
Matt007
M
P
Confused about Pct, Please help!!!
2
Replies
27
Views
6K
portmax29
P
Back
Top